Kanzhun Analyst Price Targets - Benzinga

Kanzhun Ltd

BZNASDAQ

Trade with Public

Trade with Public

$15.95

0.171.08%

At close: Aug 21, 5:00 PM EST

$15.99

0.040.25%

After Hours: Aug 21, 4:01 PM EST

Earnings: Q2 2026 earnings tomorrow on Tue Aug 25th before the market open

Conference Call: Conference call scheduled tomorrow at 8:00 AM

Click to view the webcast

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Dividends Compare Options Stock Report

Kanzhun Analyst Price Targets

Wall Street analyst price targets and consensus rating for Kanzhun (BZ).

Price Target Range — 12 Quarters

Analyst Consensus — 9 Analysts

8Buy

1Hold

Consensus RatingBuy# Analysts9Avg. Consensus PT$28Upside to Avg. PT+77.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 18, 2026	B of A Securities	Miranda Zhuang	Initiate	Neutral	$74
Jun 5, 2026	Bernstein	Robin Zhu	Upgrade	Market Perform→Outperform	$17→$18
Mar 20, 2026	Barclays	Jiong Shao	PT Cut	Overweight	$28→$19
Nov 19, 2025	Barclays	Jiong Shao	PT Raise	Overweight	$25→$28
Aug 22, 2025	Barclays	Jiong Shao	PT Raise	Overweight	$22→$25
Aug 21, 2025	UBS	Wei Xiong	Upgrade	Neutral→Buy	$26
Aug 20, 2025	Jefferies	Thomas Chong	PT Raise	Buy	$20→$24
Mar 13, 2025	Barclays	Jiong Shao	PT Raise	Overweight	$16→$22
Dec 9, 2024	Barclays	Jiong Shao	PT Raise	Overweight	$14→$16
Dec 9, 2024	Bernstein	Robin Zhu	Downgrade	Outperform→Market Perform	$19→$15
Nov 29, 2024	Citigroup	Brian Gong	PT Cut	Buy	$17→$16
Aug 30, 2024	Barclays	Jiong Shao	PT Cut	Overweight	$27→$14
May 22, 2024	UBS	Wei Xiong	PT Raise	Neutral	$22→$24
May 22, 2024	JP Morgan	Allen Li	PT Raise	Overweight	$23→$25
Mar 13, 2024	Barclays	Jiong Shao	PT Raise	Overweight	$22→$27
Mar 13, 2024	New Street Research	Jin Yoon	Upgrade	Neutral→Buy	$25
Mar 12, 2024	Macquarie	Danny Lee	Upgrade	Neutral→Outperform	—
Dec 20, 2023	New Street Research	Jin Yoon	Initiate	Neutral	$17
Dec 13, 2023	JP Morgan	Allen Li	Initiate	Overweight	$20
Sep 1, 2023	UBS	Wei Xiong	Downgrade	Buy→Neutral	$24→$17

More with Benzinga EdgeGet Access

Analyst Ratings News

This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top analysts changed outlook on top names. See analyst ratings page for all changes.

Avi Kapoor

PRO
B of A Securities Initiates Coverage On Kanzhun with Neutral Rating, Announces Price Target of $74

B of A Securities analyst Miranda Zhuang initiates coverage on Kanzhun (NASDAQ:BZ) with a Neutral rating and announces Price Target of $74.

Benzinga Newsdesk

PRO
Bernstein Upgrades Kanzhun to Outperform, Raises Price Target to $18

Bernstein analyst Robin Zhu upgrades Kanzhun (NASDAQ:BZ) from Market Perform to Outperform and raises the price target from $16.5 to $18.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Kanzhun, Lowers Price Target to $19

Barclays analyst Jiong Shao maintains Kanzhun (NASDAQ:BZ) with a Overweight and lowers the price target from $28 to $19.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Kanzhun, Raises Price Target to $28

Barclays analyst Jiong Shao maintains Kanzhun (NASDAQ:BZ) with a Overweight and raises the price target from $25 to $28.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Kanzhun, Raises Price Target to $25

Barclays analyst Jiong Shao maintains Kanzhun (NASDAQ:BZ) with a Overweight and raises the price target from $22 to $25.

Benzinga Newsdesk